Novo Nordisk's CagriSema REIMAGINE 1/2/3 Phase 3 Data Lands With Simultaneous Lancet Publication: 14.2% Weight Loss and 1.91% HbA1c Drop in Type 2 Diabetes, Beating Semaglutide Alone
Novo Nordisk presented the full REIMAGINE 1/2/3 Phase 3 program in a Sunday symposium at ADA 2026, with simultaneous publication in The Lancet Diabetes & Endocrinology (REIMAGINE 1 and 2) and The Lancet (REIMAGINE 3). REIMAGINE 2 (n=2,713; 68 weeks) showed CagriSema 2.4/2.4 mg producing 14.2% weight loss and 1.91% HbA1c reduction versus 10.2% and 1.75% for semaglutide 2.4 mg alone. REIMAGINE 1 (n=189; 40 weeks) showed 13.8% weight loss and 1.8% HbA1c drop vs placebo. REIMAGINE 3 (n=274) showed 12.0% weight loss and a 2.33% HbA1c drop when added to basal insulin.